Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
02/2012
02/23/2012WO2012022740A1 Combination treatment of multiple sclerosis
02/23/2012WO2012022737A1 Compositions and methods for improved organ transplant preservation and acceptance
02/23/2012WO2012022730A1 Diazoxide for use in the treatment of amyotrophic lateral sclerosis (als)
02/23/2012WO2012022724A1 Combination anti - cancer therapy
02/23/2012WO2012022707A1 Substituted heteroaryl spiropyrrolidine mdm2 antagonists
02/23/2012WO2012022677A2 Novel combination therapy for the treatment of cancer
02/23/2012WO2012022659A2 Synergistic activity of modulators of the no metabolism and of nadph oxidase in the sensitization of tumour cells
02/23/2012WO2012022487A1 Substituted cyclic carboxamide and urea derivatives as ligands of the vanilloid receptor
02/23/2012WO2012022478A2 Filler composition comprising beta-glucans
02/23/2012WO2012022468A2 Benzoquinone derivatives as modulators of mitchondrial function
02/23/2012WO2012022446A1 Testosterone solutions for the treatment of testosterone deficiency
02/23/2012WO2012022408A1 Pyrimidine derivatives as fak inhibitors
02/23/2012WO2012022341A1 Composition and use thereof for reducing body weight and/or improving endurance during and regeneration after a physical activity is performed
02/23/2012WO2012022299A1 Molecular switch
02/23/2012WO2012022265A1 Pyrrolopyrimidine compounds and uses thereof
02/23/2012WO2012022223A1 Composition comprising ligustroflavone, rhoifolin and hyperin, and use thereof in the preparation of a medicament
02/23/2012WO2012022121A1 Fused ring compound for use as mineralocorticoid receptor antagonist
02/23/2012WO2012022120A1 Dihydropyrazole compounds
02/23/2012WO2012022101A1 Diindolylmethane, precursor and derivatives thereof in preparation of medicaments for treating liver diseases
02/23/2012WO2012021991A1 Anti-viral carbamimidothioic acid esters
02/23/2012WO2012021985A1 Oligonucleotide chelate complexes
02/23/2012WO2012021982A1 Antifungal agents and uses thereof
02/23/2012WO2012021981A1 Novel phytochemicals from extracts of maple syrups and maple trees and uses thereof
02/23/2012WO2012021974A1 Compositions and methods for treatment of cystic fibrosis and diseases associated with aberrant protein cellular processing
02/23/2012WO2012021964A1 Compounds and therapeutic applications related to inhibition of dendritic cell immunoreceptor (dcir) activity and signaling events
02/23/2012WO2012021963A1 Novel sulfonamide compounds for inhibition of metastatic tumor growth
02/23/2012WO2012021922A1 Particulate substances comprising ceramic particles for delivery of biomolecules
02/23/2012WO2012003554A3 Compositions and methods for removal or destruction of amyloid fibril or amyloid adhesin comprising aggregates
02/23/2012WO2012003405A4 Sgc stimulators
02/23/2012WO2011163619A4 Niacin mimetics, and methods of use thereof
02/23/2012WO2011161436A3 Prevention of proteomic and genomic damage by dicarbonyl substrates of glo 1
02/23/2012WO2011158044A3 Respiratory formulations containing p38 mapk inhibitors
02/23/2012WO2011154895A3 Polynucleotide sequence, processes, composition and methods thereof
02/23/2012WO2011153542A3 Regulation of metabolism by mir-378
02/23/2012WO2011145808A3 Composition for treating chronic hepatitis b, containing clevudine and adefovir dipivoxil
02/23/2012WO2011143526A9 Topical peripheral neuro-affective (tpna) therapy
02/23/2012WO2011143347A3 Film coating composition and methods of making and using the same
02/23/2012WO2011140232A3 Desazadesferrothiocin and desazadesferrothiocin polyether analogues as metal chelation agents
02/23/2012WO2011137181A8 Synthetic oligosaccharides for moraxella vaccine
02/23/2012WO2011136700A3 Agent exhibiting the properties of a cognitive function promoter (embodiments)
02/23/2012WO2011135332A4 Nmn modulators for the treatment of neurodegenerative disorders
02/23/2012WO2011133463A3 Antimicrobial compositions comprising organic acid esters and methods for reducing virus and bacterial populations using such compositions
02/23/2012WO2011133385A3 Novel ether-based compounds and their use
02/23/2012WO2011131765A3 Artificial tear emulsion
02/23/2012WO2011130486A9 Combination treatments and formulations for cancer
02/23/2012WO2011130429A9 Methods and materials for treating lung cancer
02/23/2012WO2011130356A9 Systems and methods for activating cross-linking in an eye
02/23/2012WO2011128407A3 Substituted 2,3-dihydroimidazo[1,2-c]quinazoline-containing combinations
02/23/2012WO2011127176A3 Methods for treating or screening for compounds for the treatment of sepsis
02/23/2012WO2011127170A3 Methods for diagnosing and treating asthma
02/23/2012WO2011126903A3 Multisubstituted aromatic compounds as inhibitors of thrombin
02/23/2012WO2011126810A3 Intravaginal drug delivery device
02/23/2012WO2011119894A3 Heterocyclic compounds useful for kinase inhibition
02/23/2012WO2011119649A3 Pharmaceutical compositions containing berberine for treatment or prevention of weight gain and obesity associated with anti-psychotic drugs
02/23/2012WO2011119477A3 Pharmaceutical compositions of carvedilol salts and process for preparation thereof
02/23/2012WO2011116299A3 Myeloid derived suppressor cell inhibiting agents
02/23/2012WO2011115513A3 A cytosine analogue, a method of preparation of a cytosine analogue, a dna methyltransferase 1 inhibitor, a method for dna methylation inhibition, the use of the analogue in the treatment of diseases associated with deviations from normal dna methylation
02/23/2012WO2011113047A3 Compositions and methods for characterizing breast cancer
02/23/2012WO2011109367A4 Methods and compositions for treating or preventing symptoms of hormonal variations
02/23/2012WO2011109217A3 Methods of treating or preventing rna polymerase dependent viral disorders by administration of jak2 kinase inhibitors
02/23/2012WO2011107881A3 Compounds, compositions, formulations and their uses in the treatment diseases related to copper retention or hepatic disorders
02/23/2012WO2011106692A9 Methods of using (1s, 3s) -3-amino-4-difluoromethylenyl-1-cyclopentanoic acid
02/23/2012WO2011104637A3 Crystalline forms of the tri-mesylate salt of perphenazine-gaba and process of producing the same
02/23/2012WO2011093831A3 Effervescent formulations comprising cefprozil as active agent
02/23/2012WO2011093828A3 Solid dosage forms comprising cefprozil
02/23/2012WO2011093820A3 A pharmaceutical combination comprising tiotropium
02/23/2012WO2011093819A3 New pharmaceutical combination comprising tiotropium
02/23/2012WO2011093818A3 Pharmaceutical compositions comprising salmeterol and fluticasone
02/23/2012WO2011093811A3 Pharmaceutical preparations comprising formoterol and fluticasone
02/23/2012WO2011093810A3 Dry powder pharmaceutical composition comprising tiotropium and mometasone
02/23/2012WO2011093809A3 Dry powder pharmaceutical composition comprising tiotropium and ciclesonide
02/23/2012WO2011085126A3 Methods and compositions of targeted drug development
02/23/2012WO2011076209A3 Pharmaceutical composition comprising solvent mixture and a vitamin d derivative or analogue
02/23/2012WO2011060290A3 Immediate release tablet formulations
02/23/2012WO2011054930A3 Pharmaceutical solid dosage form
02/23/2012WO2011044502A9 Antibacterial aminoglycoside analogs
02/23/2012WO2011042463A3 Pharmaceutical composition comprising poorly soluble active ingredient and hyperbranched polymer
02/23/2012US20120046556 Methods and Kits for Preventing the Spread of Sexually Transmitted Microorganisms
02/23/2012US20120046518 Estrus Synchronization Preparations & Effective CIDR-Less Protocols
02/23/2012US20120046467 Quaternary ammonium salt compounds
02/23/2012US20120046422 Multi-Arm Block Copolymers as Drug Delivery Vehicles
02/23/2012US20120046368 Method for purifying 3,4-dihydroxyphenylglycol (dhpg) from plant products
02/23/2012US20120046367 Essential oil composition with anti-free radical ability
02/23/2012US20120046366 Extractions of Fixed Oil and Thymoquinone Rich Fractions (TQRF)
02/23/2012US20120046365 Method and Composition for Administering an NMDA Receptor Antagonist to a Subject
02/23/2012US20120046364 Novel Sulfonic Acid-Containing Thyromimetics, and Methods for Their Use
02/23/2012US20120046363 Docosahexaenoic acid for the treatment of heart failure
02/23/2012US20120046362 Antiviral agent and cleansing agent
02/23/2012US20120046361 Ethyl pyruvate compositions and methods
02/23/2012US20120046360 Formulation comprising fenofibric acid, a physiologically acceptable salt or derivative thereof
02/23/2012US20120046359 Bed bug control and repellency
02/23/2012US20120046358 Use of isothiocyanates compounds in treating prostatic diseases and skin cancer
02/23/2012US20120046357 Benzamide and Napthamide Derivatives Inhibiting Nuclear Factor-Kappa (B) - (NK-kB)
02/23/2012US20120046356 New process for preparing diketones and medicaments
02/23/2012US20120046355 Inhibitors of sialidase or sialidase-like enzymes
02/23/2012US20120046354 Anti-oxidant lozenges for the prevention and treatment of radiation induced mucositis, precancerous lesions, oral cancer and other oral cavity mucosal disorders
02/23/2012US20120046353 Cleistocalyx operculatus-derived compounds having inhibitory activities against avian and swine influenza viruses or novel influenza virus
02/23/2012US20120046352 Controlled cannabis decarboxylation
02/23/2012US20120046351 Medicinal cannabis added in food
02/23/2012US20120046350 Novel compounds, their preparation and use
1 ... 1338 1339 1340 1341 1342 1343 1344 1345 1346 1347 1348 1349 1350 1351 1352 1353 1354 1355 1356 1357 1358 ... 7860